Vulvar and Vaginal HPV Disease

Obstetrics and Gynecology Clinics of North America

Volumn 40, Issue 2, 2013, Pages 359-376

  Nelson, Erin L ^a   Stockdale, Colleen K ^b  

^a University of Texas Health Science Center   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Condyloma; Genital wart; Human papillomavirus; Vaginal intraepithelial neoplasia; Vulvar intraepithelial neoplasia

Indexed keywords

AMINOLEVULINIC ACID; BLEOMYCIN; CIDOFOVIR; DICHLOROACETIC ACID; FLUOROURACIL; GREEN TEA EXTRACT; IMIQUIMOD; PLACEBO; PODOPHYLLOTOXIN; RECOMBINANT ALPHA INTERFERON; TRICHLOROACETIC ACID; WART VIRUS VACCINE;

APPLICATION SITE BURNING; APPLICATION SITE IRRITATION; APPLICATION SITE PAIN; APPLICATION SITE ULCER; APPLICATION SITE VESICLE; BEDTIME DOSAGE; BRACHYTHERAPY; BURNING SENSATION; CANCER GRADING; CANCER PROGNOSIS; CARBON DIOXIDE LASER; CLINICAL EXAMINATION; CLINICAL FEATURE; COLPOSCOPY; CONDYLOMA ACUMINATUM; CRYOTHERAPY; DISEASE COURSE; DIZZINESS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; ELECTROSURGERY; EVENING DOSAGE; EXCISION; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 6; HYPOPIGMENTATION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; LASER SURGERY; LIFESTYLE MODIFICATION; LONG TERM CARE; MEDICAL DECISION MAKING; MORBIDITY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PATIENT SAFETY; PHASE 3 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; POSTOPERATIVE COMPLICATION; PREGNANT WOMAN; PREVALENCE; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; SKIN IRRITATION; SKIN REDNESS; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR CLASSIFICATION; UNSPECIFIED SIDE EFFECT; VAGINA CANCER; VAGINAL INTRAEPITHELIAL NEOPLASIA; VAGINITIS; VESICULAR RASH; VIRUS TRANSMISSION; VULVA CANCER; VULVA DISEASE; VULVA TUMOR; VULVAR INTRAEPITHELIAL NEOPLASIA; WIDE EXCISION;

ADOLESCENT; ADULT; AGED; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA IN SITU; COLPOSCOPY; CONDYLOMATA ACUMINATA; FEMALE; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 6; HUMANS; INTERFERON INDUCERS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PODOPHYLLOTOXIN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SEXUALLY TRANSMITTED DISEASES; TRICHLOROACETIC ACID; VAGINAL DISEASES; VAGINAL NEOPLASMS; VAGINAL SMEARS; VULVAR DISEASES; VULVAR NEOPLASMS; YOUNG ADULT;

EID: 84878649970     PISSN: 08898545     EISSN: 15580474     Source Type: Journal    
DOI: 10.1016/j.ogc.2013.03.003     Document Type: Review

References (60)

1. Myers E.R., McCrory D.C., Nanda K., et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000, 151:1158-1171.
2. Dunne E.F., Unger E.R., Sternberg M., et al. Prevalence of HPV infection among females in the United States. JAMA 2007, 297(8):813-819.
3. Winer R.L., Feng Q., Hughes J.P., et al. Risk of female human papillomavirus acquision associated with first male sex partner. J Infect Dis 2008, 197:279-282.
4. Rodriguez A.C., Schiffman M., Herrero R., et al. Rapid clearance of human papillomavirus and implications of clinical focus on persistent infections. J Natl Cancer Inst 2008, 100:513-517.
5. Gravitt P.E. The known unknowns of HPV natural history. J Clin Invest 2011, 121(12):4593-4599.
6. Garland S.M., Steben M., Sings H.L., et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase iii trials of a quadrivalent vaccine. J Infect Dis 2009, 199:805-814.
7. FutureI/II Study Group Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomized controlled trial. BMJ 2010, 340:c3493.
8. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997, 102:3-8.
9. Lacey C.J., Lowndes C., Shah K. Burden and management of noncancerous HPV related-conditions; HPV 6/11 disease. Vaccine 2006, 24(Suppl 3):S35-S41.
10. Beutner K.R., Richwald G.A., Wiley D.J., et al. External genital warts: report of the American Medical Association Consensus Conference. AMA Expert Panel on External Genital Warts. Clin Infect Dis 1998, 27(4):796-806.
11. American College of Obstetricians and Gynecologists Cervical Cytology Screening. ACOG Practice Bulletin No 131. Obstet Gynecol 2012, 120:1222-1238.
12. Hu D., Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol 2008, 198:500.e1-500.e7.
13. Kennedy C.M., Boardman L.A. New approaches to external genital warts and vulvar intraepithelial neoplasia. Clin Obstet Gynecol 2008, 51(3):518-526.
14. Centers for Disease Control and Prevention Sexually transmitted diseases treatment guidelines 2010. MMWR Recomm Rep 2010, 59(RR-12):1-117.
15. Wiley D.J., Douglas J., Beutner K., et al. External genital warts: diagnosis, treatment and prevention. Clin Infect Dis 2002, 35(Suppl 2):S10-S24.
16. Beutner K.R., Wiley D.J., Douglas J.M., et al. Genital warts and their treatment. Clin Infect Dis 1999, 28:S37-S56.
17. van Seters M., van Beurden M., deCraen A.J. Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. Gynecol Oncol 2005, 97:645-651.
18. Jones R.W., Rowan D.M. Vulvar intraepithelial neoplasia III: a clinical study of the outcome in 113 cases with relation to the later development of invasive vulvar carcinoma. Obstet Gynecol 1994, 84:741-745.
19. Jones R.W., Rowan D.M., Stewart A.W. Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstet Gynecol 2005, 106(6):1319-1326.
20. Darragh T.M., Colgan T.J., Cox J.T., et al. The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med 2012, 136:1-32.
21. Watson M., Saraiya M., Wu X. Update of HPV-associated female genital cancers in the United States, 1999-2004. J Womens Health 2009, 18(11):1731-1738.
22. Smith J.S., Backes D.M., Hoot B.E., et al. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. Obstet Gynecol 2009, 113(4):917-924.
23. American College of Obstetricians and Gynecologists Management of vulvar intraepithelial neoplasia. Committee Opinion No 509. Obstet Gynecol 2011, 118:1192-1194.
24. Mathiesen O., Buus S.K., Cramers M. Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomized, double-blinded study. Gynecol Oncol 2007, 107(2):219-222.
25. van Seters M., van Beurden M., ten Kate F.J., et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med 2008, 358(14):1465-1473.
26. Terlou A., van Seters M., Ewing P.C., et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow-up of a randomized clinical trial. Gynecol Oncol 2011, 121:157-162.
27. Hillemanns P., Wang X., Staehle S., et al. Evaluation of different treatment modalities for vulvar intraepithelial neoplasia (VIN): CO2 laser vaporization, photodynamic therapy, excision and vulvectomy. Gynecol Oncol 2006, 100:271-275.
28. von Gruenigen V.E., Gibbons H.E., Gibbins K., et al. Surgical treatments for vulvar and vaginal dysplasia: a randomized controlled trial. Obstet Gynecol 2007, 109(4):942-947.
29. Society of Gynecologic Oncologists Medical Practice and Ethics Committee SGO clinical practice guidelines: management of gynecologic cancers 1996, Society of Gynecologic Oncologists, Chicago.
30. Modesitt S.C., Waters A.B., Walton L., et al. Vulvar intraepithelial neoplasia III: occult cancer and the impact of margin status on recurrence. Obstet Gynecol 1998, 92:962-966.
31. Thueson B., Andreasson B., Bock J.E. Sexual function and somatopsychic reactions after local excision of vulvar intra-epithelial neoplasia. Acta Obstet Gynecol Scand 1992, 71(2):126-128.
32. Riberio F., Figueiredo A., Paula T., et al. Vulvar intraepithelial neoplasia: evaluation of treatment modalities. J Low Genit Tract Dis 2012, 16(3):313-317.
33. Wallbillich J.J., Rhodes H.E., Milbourne A.M., et al. Vulvar intraepithelial neoplasia (VIN 2/3): comparing clinical outcomes and evaluating risk factors for recurrence. Gynecol Oncol 2012, 127(2):312-315.
34. Edwards C.L., Tortolero-Luna G., Linares A.C., et al. Vulvar intraepithlial neoplasia and vulvar cancer. Obstet Gynecol Clin North Am 1996, 23:295-324.
35. Joura E.A., Leodolter S., Hernandez-Avila M., et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007, 369(9574):1693-1702.
36. Sillman F.H., Fruchter R.G., Chen Y.S., et al. Vaginal intraepithelial neoplasia: risk factors for persistence, recurrence and invasion and its management. Am J Obstet Gynecol 1997, 176:93-99.
37. Woodruff J.D. Carcinoma in situ of the vagina. Clin Obstet Gynecol 1981, 24:485-501.
38. Bornstein J., Kaufman R.H., Adam E., et al. Human papillomavirus associated with vaginal intraepithelial neoplasia in women exposed to diethylstilbesterol in utero. Obstet Gynecol 1987, 70:75-80.
39. Robboy S.J., Noller K.L., Obrien P., et al. Increased incidence of cervical and vaginal dysplasia in 3,980 diethylstilbestrol-exposed young women. JAMA 1984, 252(21):2979-2983.
40. Manetta A., Gutrecht E.L., Berman M.L., et al. Primary invasive carcinoma of the vagina. Obstet Gynecol 1990, 76:639-642.
41. Gemmell J., Holmes D.M., Duncan I.D. How frequently need vaginal smears be taken after hysterectomy for cervical intraepithelial neoplasia?. Br J Obstet Gynaecol 1990, 97:58-61.
42. Schockeart S., Poppe W., Arbyn M., et al. Incidence of vaginal intraepithelial neoplasia after hysterectomy for cervical intraepithelial neoplasia: a retrospective study. Am J Obstet Gynecol 2008, 199:113.e1-113.e5.
43. Gagne H.M. Colposcopy of the vagina and vulva. Obstet Gynecol Clin North Am 2008, 35:659-669.
44. Dodge J.A., Eltabbakh G.H., Mount S.L., et al. Clinical features and risk of recurrence among patients with vaginal intraepithelial neoplasia. Gynecol Oncol 2001, 83:363-369.
45. Caglar H., Hertzog R.W., Hreshchyshyn M.M. Topical 5-fluorouracil treatment of vaginal intraepithelial neoplasia. Obstet Gynecol 1981, 58:580-583.
46. Kirwan P. Topical 5-fluorouracil in the treatment of vaginal intraepithelial neoplasia. Br J Obstet Gynaecol 1985, 92:287-291.
47. Audet-LaPoint P., Body G., Vauclar R., et al. Vaginal intraepithelial neoplasia. Gynecol Oncol 1990, 36:232-239.
48. Haidopoulos D., Diakomanolis E., Rodolakis A., et al. Can local application of imiquimod cream be an alternative mode of therapy for patients with high-grade intraepithelial lesions of the vagina?. Int J Gynecol Cancer 2005, 15:898-902.
49. Diakomanolis E., Haidopoulos D., Stefanidis K. Treatment of high-grade vaginal intraepithelial neoplasia with imiquimod cream. N Engl J Med 2002, 347:374.
50. Lin J., Juang E.Y., Chang H.Y., et al. Therapeutic effect of topical applications of tricholoracetic acid for vaginal intraepithelial neoplasia after hysterectomy. Jpn J Clin Oncol 2005, 35(11):651-654.
51. Hoskins W., Perez C. Treatment of VaIN. The principles and practice of gynecologic oncology 2000, 820-821. Lippincott, Williams, and Wilkins, New York. 3rd edition. W. Hoskins, C.A. Perez, R.C. Young (Eds.).
52. Graham K., Wright K., Cadwallader B., et al. 20-year retrospective review of medium dose rate intracavitary brachytherapy in VAIN3. Gynecol Oncol 2007, 106:105-111.
53. Blanchard P., Monnier L., Dumas I., et al. Low dose rate definitive brachytherapy for high-grade vaginal intraepithelial neoplasia. Oncologist 2011, 16:182-188.
54. Matsuo K., Chi D.S., Walker L.D., et al. Ultrasonic surgical aspiration for vaginal intraepithelial neoplasia. Int J Gynaecol Obstet 2009, 105:71-73.
55. Robinson J.B., Sun C.C., Bodurka-Bevers D., et al. Cavitational ultrasonic surgical aspiration for the treatment of vaginal intraepithelial neoplasia. Gynecol Oncol 2000, 78:235-241.
56. Gurumurthy M., Curickshank M. Management of vaginal intraepithelial neoplasia. J Low Genit Tract Dis 2012, 16(3):306-312.
57. Diaz M.L. Prevention of cervical, vaginal and vulval cancers: role of the quadrivalent human papillomavirus (6, 11, 16, 18) recombinant vaccine. Int J Womens Health 2009, 1:119-129.
58. HPV PATRICIA Study Group Overall efficacy of HPV 16/18 ASO4-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia; 4-year end-of-study analysis of the randomised double-blind PATRICIA trial. Lancet Oncol 2012, 13(1):89-99.
59. DeVuyst H., Clifford G.M., Nascimento M.C., et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009, 124:1626-1636.
60. Chaturvedi A.K. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health 2010, 46:S20-S26.